Blackstone has turned its sights on the small, albeit growing rooftop solar panel installation market, a niche already controlled by Elon Musk and his cousins via SolarCity. Carved out of assets that Blackstone acquired in 2012, Vivint Solar last week entered registration with a proposed US$200m IPO.
Good news travels fast in the biotech world. Roche’s planned US$8.3bn takeover of InterMune has stirred-up interest among life sciences new issues, providing some assurance that the historic pricing window for the IPO market’s most speculative niche will remain open through the Labor Day break.
Atara Biotherapeutics has postponed its IPO ahead of expected pricing this evening, despite strong investor demand for the offering. The decision to postpone followed the receipt by the company of data on ongoing clinical trials, according to several market sources close to the situation.